Utah Medical Products (UTMD) EBITDA Margin (2010 - 2026)

Utah Medical Products' EBITDA Margin history runs 17 years deep, the most recent figure standing at 24.09% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 1462.0% year-over-year to 24.09%; the TTM figure through Mar 2026 stood at 32.29% (down 96.0% YoY), while the FY2025 annual figure was 35.77%, up 490.0% from the prior year.
• EBITDA Margin was 24.09% for Q1 2026 at Utah Medical Products, down from 31.93% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 51.17% in Q4 2022 to a low of 9.65% in Q4 2024.
• Historically, EBITDA Margin has averaged 31.44% across 5 years, with a median of 31.93% in 2025.
• Biggest YoY gain for EBITDA Margin was 2655 bps in 2024; the steepest drop was 3596 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 51.17% in 2022, then retreated by 11 bps to 45.62% in 2023, then plunged by 79 bps to 9.65% in 2024, then surged by 231 bps to 31.93% in 2025, then retreated by 25 bps to 24.09% in 2026.
• The last three EBITDA Margin figures came in at 24.09% (Q1 2026), 31.93% (Q4 2025), and 22.98% (Q3 2025), per Business Quant data.